The continuing problem of human African trypanosomiasis (sleeping sickness)

Annals of Neurology

Volumn 64, Issue 2, 2008, Pages 116-126

  Kennedy, Peter G E ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PAFURAMIDINE; PENTAMIDINE; SURAMIN;

AFRICAN TRYPANOSOMIASIS; AGRANULOCYTOSIS; ANAPHYLACTIC SHOCK; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAIN DISEASE; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMA; CONTINUOUS INFUSION; DRUG INDUSTRY; ENCEPHALITIS; EPILEPTIC STATE; GASTROINTESTINAL SYMPTOM; GOVERNMENT; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; INFLAMMATORY DISEASE; KIDNEY FAILURE; LIVER TOXICITY; LUMBAR PUNCTURE; MONOTHERAPY; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PARASITE TRANSMISSION; PARASITE VIRULENCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEIZURE; SENSORY DYSFUNCTION; SKIN DEFECT; SLEEP DISORDER; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE; TSETSE FLY; VISUAL DISORDER;

ANIMALS; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN; TSETSE FLIES;

EID: 51549108736     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21429     Document Type: Review

References (63)

1. Kennedy PGE. The fatal sleep. Edinburgh, United Kingdom: Luath Press Limited, 2007.
2. Epidemiology and control of African trypanosomiasis. Report of a WHO expert committee. Geneva, Switzerland: World Health Organization Technical Report Series, 1986;739.
3. Kennedy PGE. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004;113:496-504.
4. Atouguia JLM, Kennedy PGE. Neurological aspects of human African trypanosomiasis. In: Davis LE, Kennedy PGE, eds. Infectious diseases of the nervous system. Oxford: Butterworth-Heinemann, 2000:321-372.
5. Vickerman K. Landmarks in trypanosome research. In: Hide G, Mottram JC, Coombs GH, Holmes PH, eds. Trypanosomiasis and leishmaniasis. Oxford: CAB International, 1997:1-37.
6. Williams BI. African trypanosomiasis. In Cox FEAG, ed. The Wellcome Trust illustrated history of tropical diseases. London: The Wellcome Trust, 1996:178-191.
7. Bentivoglio M, Grassi-Zucconi G, Kristensson K. From trypanosomes to the nervous system, from molecules to behaviour: a survey, on the occasion of the 90th anniversary of Castellani's discovery of the parasites in sleeping sickness. Ital J Neurol Sci 1994;15:77-89.
8. Pepin J. Combination therapy for sleeping sickness: a wake-up call. J Infect Dis 2007;195:311-313.
9. Control and surveillance of African trypanosomiasis. Report of a WHO expert committee. Geneva, Switzerland: World Health Organization Technical Report Series, 1998;881.
10. WHO African trypanosomiasis (sleeping sickness) Fact sheet No 259. Revised August 2006. www.who.int/mediacentre/factsheets/fs259/en
11. Kuzoe FA. Current situation of African trypanosomiasis. Acta Trop 1993;54:153-162.
12. Lejon V, Boelaert M, Jannin J, et al. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect Dis 2003;3:804-808.
13. Kennedy PGE. Sleeping sickness - human African trypanosomiasis. Pract Neurol 2005;5:260-267.
14. Berriman M, Ghedin E, Hertz-Fowler C, et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005;309:416-422.
15. Donelson JE. Antigenic variation and the African trypanosome genome. Acta Trop 2002;85:391-404.
16. Apted FIC. Clinical manifestations and diagnosis of sleeping sickness. In: Mulligan HW ed. The African trypanosomiases. London: George Allen & Unwin, 1970:551-583.
17. Duggan AJ, Hutchington MP. Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg 1966;69:124-131.
18. Buguet A, Bisser S, Josenando T, et al. Sleep structure: a new diagnostic tool for stage determination in sleeping sickness. Acta Trop 2005;93:107-117.
19. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006;97:55-64.
20. Truc P, Lejon V, Magnus E, et al. Evaluation of the microCATT, CATT/Trypanosoma brucei gambiense, and LATEX/T.b. gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa. Bull World Health Organ 2002;80:882-886.
21. Jamonneau V, Solano P, Garcia A, et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire. Trop Med Int Health 2003;8:589-594.
22. Njiru ZK, Mikosza ASJ, Armstrong T, et al. Loop-mediated isothermal amplification (LAMP) method for rapid detection of Trypanosoma brucei rhodesiense. PLos Negl Trop Dis 2008;2:147-154.
23. Fairlamb AH. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol 2003;19:488-494.
24. Lejon V, Büscher P. Cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Intl Health 2005;10:395-403.
25. Lejon v, Reiber H, Legros D, et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 2003;187:1475-1483.
26. Chappuis F, Loutan L, Simarro P, et al. Options for field diagnosis of Human African Trypanosomiasis. Clin Microbiol Rev 2005;18:133-146.
27. Kennedy PGE. Diagnosing central nervous system trypanosomiasis: two stage or not to stage? Trans R Soc Trop Med Hyg 2008;102:306-307.
28. Sabbah P, Brosset C, Imbert P, et al. Human African trypanosomiasis: MRI. Neuroradiology 1997;39:708-710.
29. Gill DS, Chatha DS, del Carpio-O'Donovan R. MR Imaging findings in African trypanosomiasis. Am J Neuroradiol 2003;24:1383-1385.
30. Braakman HMH, van de Molengraft FJJM, Hubert WWA, Boerman DH. Lethal African trypanosomiasis in a traveler: MRI and neuropathology. Neurology 2006;66:1094-1096.
31. Kumar N, Orenstein R, Uslan DZ, et al. Melarsoprol-associated multifocal inflammatory CNS illness in African trypanosomiasis. Neurology 2006;66:1120-1121.
32. Kennedy PGE. Human African trypanosomiasis: in and out of Africa. Neurology 2006;66:962-963.
33. Fairlamb AH. Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis. Trans R Soc Trop Med Hyg 1990;84:613-617.
34. Burri C, Nkunku S, Merolle A, et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000;355:1419-1425.
35. Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994;33:1-47.
36. Bisser S, N'Siesi FX, Lejon V, et al. Equivalence trial of Melarsoprol and Nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007;195:322-329.
37. Legros D, Evans S, Maiso F, et al. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1994;93:439-442.
38. Priotto G, Kasparian S, Ngouama D, et al. Nifurtimox-Eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007;45:1435-1442.
39. Checchi F, Piola P, Ayikoru H, et al. Nifurtimox plus Eflornithine for late-stage sleeping sickess in Uganda: a case series. PLos Negl Trop Dis 2007;1:64-69.
40. Lejon V, Robays J, N'Siesi FX, et al. Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness. Clin Vaccine Immunol 2007;14:732-737.
41. Adams JH, Haller L, Boa FY, et al. Human African trypanosomiasis (T./b.gambiense): a study of 16 fatal cases of sleeping sickness with some observations on acute reactive arsenical encephalopathy. Neuropathol Appl Neurobiol 1986;12:81-94.
42. Pentreath VW, Kennedy PGE. Pathogenesis of human African trypanosomiasis. In: Maudlin I, Holmes PH, Miles MA, eds. The Trypanosomiases. Oxford: CAB International, 2004: 283-301.
43. Cook GC. Protozoan and helminthic infections. In: Lambert HP, ed. Infections of the central nervous system. Philadelphia: BC Dekker, 1991:264-282.
44. Kennedy PGE. The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of human African trypanosomiasis. J Neuroimmunol 1999;100:36-41.
45. Kennedy PGE. Diagnostic and neuropathogenesis issues in human African trypanosomiasis. Intl J Parasitol 2006;36:505-512.
46. MacLean L, Odiit M, MacLeod A, et al. Spatially and genetically distinct African trypanosome virulence variants defined by host interferon-y response. J Infect Dis 2007;196:1620-1628.
47. MacLean L, Odiit M, Sternberg JM. Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis 2001;184:1086-1090.
48. Kennedy PGE. Animal models of human African trypanosomiasis - very useful or too far removed? Roy Soc Trop Med Hyg 2007;101:1061-1062.
49. Hunter CA, Jennings FW, Adams JH, et al. Sub-curative chemotherapy and fatal post-treatment reactive encephalopathies in African trypanosomiasis. Lancet 1992;339:956-958.
50. Hunter CA, Jennings FW, Kennedy PGE, Murray M. Astrocyte activation correlates with cytokine production in central nervous system of Trypanosoma brucei brucei-infected mice. Lab Invest 1992;67:635-642.
51. Kennedy PGE, Rodgers J, Jennings FW, et al. A Substance P antagonist, RP-67,580 ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc Natl Acad Sci USA 1997;94:4167-4170.
52. Hunter CA, Gow JW, Kennedy PGE, et al. Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice. Infect Immun 1991;5:4636-4640.
53. Sternberg JM, Rodgers J, Bradley B, et al. Meningoencephalitic African trypanosomiasis: brain IL-10 and IL-6 are associated with protection from neuroinflammatory pathology. J Neuroimmunol 2005;167:81-89.
54. Kennedy PGE, Rodgers J, Bradley B, et al. Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. Brain 2003;126:1683-1690.
55. Barkhulzen M, Magez S, Atkinson RA, Brombacher F. Interleukin-12p70- dependent interferon-gamma production is crucial for resistance in African trypanosomiasis. Infect Dis 2007;196:1253-1260.
56. Hunter CA, Jennings FW, Kennedy PGE, Murray M. The use of azathioprine to ameliorate post-treatment encephalopathy associated with African trypanosomiasis. Neuropathol Appl Neurobiol 1992;18:619-662.
57. Jennings FW, Gichuki CW, Kennedy PGE, et al. The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis. Neuropathol Appl Neurobiol 1997;23:225-234.
58. Jennings FW, Rodgers J, Bradley B, et al. Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen. Parasitol Intl 2002;51:381-388.
59. Schultzberg M, Ambatsis M, Samuelsson EB, et al. Spread of trypanosoma brucei to the nervous system: early attack on circumventricular organs and sensory ganglia. J Neurosci Res 1988;21:56-61.
60. Masocha W, Robertson B, Rottenberg ME, et al. Cerebral vessel laminins and IFN-γ define trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest 2004;114:689-694.
61. Bentivoglio M, Grassi-Zucconi G, Olsson T, Kristensson K. Trypanosoma brucei and the nervous system. Trends Neurosci 1994;17:325-329.
62. Bentivoglio M, Kristensson K. Neural-immune interactions in disorders of sleep-wakefulness organization. Trends Neurosci 2007;30:645-652.
63. Barrett MP, Burchmore RJS, Stich A, et al. The trypanosomiases. Lancet 2003;362:1469-1480.